Results 91 to 100 of about 11,886 (196)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +1 more source

Eculizumab [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

The use of eculizumab in renal transplantation [PDF]

, 2013
The complement system plays a vital role in mediating disease processes within renal allografts. Eculizumab is a humanized monoclonal antibody that targets complement protein C5, inhibiting cleavage into C5a and C5b, and therefore preventing formation of
Dorling, Anthony; id_orcid, Sacks, Steven H; id_orcid, Chowdhury, Paramit, Barnett, A Nicholas R, Asgari, Elham, Mamode, Nizam   +5 more
core   +1 more source

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment

Blood Advances
: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour   +10 more
doaj   +1 more source

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen   +4 more
doaj   +1 more source

Behandling med eculizumab vid katastrofalt antifosfolipidsyndrom [PDF]

, 2018
Bakgrund: Eculizumab (Solirisâ) är en monoklonal antikropp som är riktad mot C5 i komplementsystemet. Bindning av eculizumab till C5 förhindrar proteinets klyvning och därmed också aktivering.
Cronin, Jennifer
core  

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report

Case Reports in Neurology
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG.
Nadia Khalil, Claudia Guerra Hernandez, Jerrica Farias, Kathleen Murray, Niraja Suresh, Clifton Gooch, Tuan H. Vu   +6 more
doaj   +1 more source

Disseminated cryptococcosis associated with administration of eculizumab. [PDF]

, 2018
PURPOSE: A case report of fatal disseminated cryptococcosis in a patient treated with eculizumab is presented along with a review of literature suggesting a possible etiologic mechanism.
Iaderosa, Roberto, McGhan, Ryan, Aldrich, Christina, Gitomer, Jeremy, Stevens, Ryan, Clancy, Megan, Inocencio, Ana Marie   +6 more
core  

Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome [PDF]

, 2017
Background: Kidney transplantation in patients with atypical haemolytic uraemic syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in graft loss. Eculizumab prophylaxis prevents recurrence, improving graft survival.
Wetzels, J.F.M., Brand, J. van den, Adang, E.M.M., Verhave, J.C.   +3 more
core   +1 more source

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival [PDF]

, 2011
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder with increased mortality and morbidity resulting from intravascular hemolysis.
Richard J. Kelly, Dena R. Cohen, Walter M. Gregory, Peter Hillmen, Lindsay D. Mitchell, Stephen J. Richards, Matthew Cullen, Louise M. Arnold, Anita Hill, Gemma L. Brooksbank   +9 more
core   +1 more source